325 related articles for article (PubMed ID: 2953870)
21. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
[No Abstract] [Full Text] [Related]
22. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
23. Can combined DES and LHRH depot therapy (ICI 118630) prevent endocrinologic and clinical flare-up in metastatic prostate cancer?
Fernandez del Moral P; Litjens TT; Weil EH; Debruyne FM
Urology; 1988 Aug; 32(2):137-40. PubMed ID: 2969641
[TBL] [Abstract][Full Text] [Related]
24. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
25. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
26. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
[TBL] [Abstract][Full Text] [Related]
28. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Murphy GP; Greco J; Huben R
Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
[TBL] [Abstract][Full Text] [Related]
29. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
[TBL] [Abstract][Full Text] [Related]
30. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
[TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
32. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
[TBL] [Abstract][Full Text] [Related]
33. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
Matta WH; Shaw RW; Burford GD
Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
[TBL] [Abstract][Full Text] [Related]
34. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
[TBL] [Abstract][Full Text] [Related]
35. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
[TBL] [Abstract][Full Text] [Related]
36. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
37. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
Goldspiel BR; Kohler DR
DICP; 1991; 25(7-8):796-804. PubMed ID: 1835221
[TBL] [Abstract][Full Text] [Related]
38. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
39. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
40. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
West CP; Baird DT
Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
